Therefore, serum HB-EGF detected by the newly developed method can be an early diagnostic marker for ovarian cancer

Therefore, serum HB-EGF detected by the newly developed method can be an early diagnostic marker for ovarian cancer. HB-EGF is also expressed in a variety of human carcinomas such as pancreatic, esophageal, colon, gastric, and bladder cancers [9], and targeting it therapeutically HSP70-IN-1 is under clinical evaluation [22]. of HB-EGF in 20 ovarian cancer patients and 20 healthy volunteers, ovarian cancer patients showed significantly higher concentrations than healthy volunteers (test. The result of the test was test was em P /em 0.05, suggesting that there was a statistically significant difference between the values of healthy volunteers and ovarian cancer patients. Table 2 Clinical characteristics of ovarian cancer patients examined and HB-EGF concentrations determined by immuno-PCR thead th align=”left” rowspan=”1″ colspan=”1″ Lot No. /th th align=”left” rowspan=”1″ colspan=”1″ Age /th th align=”left” rowspan=”1″ colspan=”1″ Medication /th th align=”left” rowspan=”1″ colspan=”1″ Stage and condition /th th align=”left” rowspan=”1″ colspan=”1″ HB-EGF (pg/mL) /th /thead BRH46917076Neulasta, Lisinopril, Calcium, Fish oil, Crestor, ValtrexFlare-up: IV recurrence7.35BRH46917160Lisinopril, ASA, Atenolol, Nifedipine, Miralax, Vitamins, ClonidineStable: IIIC, T2cNIMX30.1BRH46917257Valtrex, Premarin, Coumadin, Ambien, Restasis, Gelclair GelIV, Stable66.6BRH46917361levothyroxine, provastatinRemission35.1BRH46917475Synthroid, Lisinopril, Omeprazole, Celexa, ASA, MultivitaminStable52.1BRH46917554Metformin, Travatan, Crestor, Alphagen, Insulin, Victosa, Micardis, NeulastaRemission47.5BRH46917675Enalapril, Centrum Silver, Vitamin B-12, B-6, Calcium CitrateIV, Stable51.4BRH41063242DoxilIV22.1BRH41063367Taxol, CarboplatinIII18.1BRH41063584Taxol, CarboplatinII22.4BRH50138174Carboplatin, Synthroid, Taxol, Metoprolol, Heparin Lock, Simvastatin, MetforminIII34.2BRH50138268Xanax, Coumadin, Bystolic, Carboplatin, Doxil, AvastinIV14.0BRH50138363Carvedilol, TamoxifenIII14.2BRH50138453TaxolIIIB30.0BRH50138572Glipizide, Metoprolol Succinate, HaldolIII5.79BRH50138655Synthroid, Taxol, CarboplatinIA LLOQBRH50138757Coumadin, EndocetIIIC6.76BRH50138893Atenolol, Doxazosin, Lasix, Synthroid, Omeprazole, ASA, Vitamin C, Vitamin D, Oxybitymine, Magnesium, Potassium, Simvastatin, Aricept, HycamtinIII27.4BRH50138961Toprol, Digoxin, Femara, AmeprazoleII47.4BRH50139066Crestor, Omega 3, Calcium, Vitamins, ASA, GlucosamineIII35.3 Open in a separate window Discussion In this study, we successfully developed a highly sensitive immuno-PCR method for the determination of soluble HB-EGF concentrations in human serum with acceptable accuracy and precision (Table 1). The method showed no cross-reactivity with other EGF family proteins such HSP70-IN-1 as EGF and TGF-, and had no cross-reactivity with HGF which has an affinity for heparin (Figure 2). With our newly developed method, we measured HSP70-IN-1 soluble HB-EGF in human serum and demonstrated a statistically significant difference in soluble HB-EGF concentrations between sera of healthy volunteers and ovarian cancer patients (Figure 3). There are some academic papers reporting about human serum or plasma concentrations of HB-EGF. Yamada et al. developed a sandwich ELISA combined with enrichment process by using heparin and demonstrated that HSP70-IN-1 the mean plasma HB-EGF concentration of the 95 healthy volunteers was 15.9 pg/mL [15]. Matsumoto et al. demonstrated that mean plasma HB-EGF levels in the coronary artery disease Rabbit Polyclonal to MYST2 (CAD) patients and non-CAD patients were 164.3 and 62.6 pg/mL, respectively, with the same method as above [16]. On the other hand, a competitive ELISA developed by Sanchez-vizcaino et al. determined serum HB-EGF in the range of 0.03-3 nM and the mean serum HB-EGF concentrations in women and men were 0.26 nM and 0.28 nM (approx. 3 ng/mL), respectively [17]. According to a report from Keay et al., the mean concentrations of soluble HB-EGF in sera from interstitial cystitis cases and normal controls were 2.3 and 9.1 ng/mL, respectively [18]. Another report from the same authors group showed that the mean urine concentration of soluble HB-EGF was strikingly lower in interstitial cystitis patient specimens (1.53 ng/mL) as compared to asymptomatic controls (6.33 ng/mL) or patients with bacterial cystitis (5.15 ng/mL) [19]. Their method is not a sandwich ELISA but a sample (e.g. serum, cell lysate, or urine)-coated ELISA which seems to prone to produce non-specificity. The differences in the range of HB-EGF levels in serum or plasma between previous reports seem to be due to the difference in HSP70-IN-1 measurement principle. Our method utilizes KM3566 as a capture antibody. KM3566 neutralizes HB-EGF activity in a way KM3566 inhibits the binding of HB-EGF to its receptors [20]. Therefore, only an active form of soluble HB-EGF, which has a potency to bind to its receptors, should be captured by KM3566, and then, detected by the polyclonal anti-HB-EGF antibody. In our recent report, we demonstrated that soluble HB-EGF levels in sera of ovarian cancer patients were higher than those in controls using the commercially available kit with some modifications of protocol [21]. Compared to the results with the kit in the previous study, soluble HB-EGF levels determined by the newly developed immuno-PCR in this study were relatively lower but the difference between healthy volunteers and ovarian cancer patients was clearer. This can be explained that our newly developed method detects only an active form.